Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sytske Anne Bergstra

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Annals of the Rheumatic Diseases|March 9, 2026
Hand-dominant joint involvement pattern associates with favourable, and polyarthritis with unfavourable, treatment response to both csDMARDs and bDMARDs in early rheumatoid arthritis: a combined analysis of NORD-STAR and BeSt trialsYasuo Nagafuchi, Tjardo D Maarseveen, Kristina Lend, et al.
Joint Bone Spine|December 2, 2023
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studiesKim Lauper, Denis Mongin, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases|September 13, 2022
After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registriesManuel Pombo-Suarez, Carlos Sanchez-Piedra, Juan Gómez-Reino, et al.
Rheumatology (Oxford, England)|August 19, 2020
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesDelphine S Courvoisier, Katarina Chatzidionysiou, Denis Mongin, et al.
Seminars in Arthritis and Rheumatism|November 14, 2018
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysisJocelyn Quistrebert, Signe Hässler, Delphine Bachelet, et al.
Annals of the Rheumatic Diseases|June 15, 2022
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaborationKim Lauper, Michele Iudici, Denis Mongin, et al.
Annals of the Rheumatic Diseases|December 10, 2023
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)Romain Aymon, Denis Mongin, Sytske Anne Bergstra, et al.
NPJ Digital Medicine|October 23, 2025
Location and amount of joint involvement differentiates rheumatoid arthritis into different clinical subsetsTjardo D Maarseveen, Marc P Maurits, Lavinia Agra Coletto, et al.
Annals of the Rheumatic Diseases|November 10, 2022
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 updateJosef S Smolen, Robert B M Landewé, Sytske Anne Bergstra, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Annals of the Rheumatic Diseases|March 9, 2026
Hand-dominant joint involvement pattern associates with favourable, and polyarthritis with unfavourable, treatment response to both csDMARDs and bDMARDs in early rheumatoid arthritis: a combined analysis of NORD-STAR and BeSt trialsYasuo Nagafuchi, Tjardo D Maarseveen, Kristina Lend, et al.
Joint Bone Spine|December 2, 2023
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studiesKim Lauper, Denis Mongin, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases|September 13, 2022
After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registriesManuel Pombo-Suarez, Carlos Sanchez-Piedra, Juan Gómez-Reino, et al.
Rheumatology (Oxford, England)|August 19, 2020
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registriesDelphine S Courvoisier, Katarina Chatzidionysiou, Denis Mongin, et al.
Seminars in Arthritis and Rheumatism|November 14, 2018
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysisJocelyn Quistrebert, Signe Hässler, Delphine Bachelet, et al.
Annals of the Rheumatic Diseases|June 15, 2022
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaborationKim Lauper, Michele Iudici, Denis Mongin, et al.
Annals of the Rheumatic Diseases|December 10, 2023
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)Romain Aymon, Denis Mongin, Sytske Anne Bergstra, et al.
NPJ Digital Medicine|October 23, 2025
Location and amount of joint involvement differentiates rheumatoid arthritis into different clinical subsetsTjardo D Maarseveen, Marc P Maurits, Lavinia Agra Coletto, et al.
Annals of the Rheumatic Diseases|November 10, 2022
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 updateJosef S Smolen, Robert B M Landewé, Sytske Anne Bergstra, et al.
Pageof 6